Lucid Diagnostics Inc. (LUCD)

$3.35

-0.04 (-1.18%)
Rating:
Recommendation:
-
Symbol LUCD
Price $3.35
Beta 0.000
Volume Avg. 0.10M
Market Cap 128.156M
Shares () -
52 Week Range 1.69-13.52
1y Target Est -
DCF Unlevered LUCD DCF ->
DCF Levered LUCD LDCF ->
ROE 0.67% Neutral
ROA -65.01% Strong Sell
Operating Margin -
Debt / Equity 33.49% Neutral
P/E -
P/B 2.53 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LUCD news


Healthcare
Medical Devices
NASDAQ Global Market

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.